topotecan has been researched along with adamantane in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Korchagina, DV; Lavrik, OI; Nefedov, AA; Ponomarev, KY; Reynisson, J; Rogachev, AD; Salakhutdinov, NF; Suslov, EV; Volcho, KP; Zafar, A; Zakharenko, AL; Zakharova, OD | 1 |
| Dyrkheeva, NS; Gatilov, YV; Ilina, ES; Ivankin, DI; Korchagina, DV; Kornienko, TE; Lavrik, OI; Malakhova, AA; Munkuev, AA; Reynisson, J; Salakhutdinov, NF; Suslov, EV; Volcho, KP; Zakharenko, AL | 1 |
2 other study(ies) available for topotecan and adamantane
| Article | Year |
|---|---|
Aminoadamantanes containing monoterpene-derived fragments as potent tyrosyl-DNA phosphodiesterase 1 inhibitors.
Topics: Adamantane; Amines; Antineoplastic Agents; Binding Sites; Drug Screening Assays, Antitumor; Drug Synergism; HCT116 Cells; Humans; Molecular Docking Simulation; Monoterpenes; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Stereoisomerism; Topotecan | 2018 |
Adamantane-Monoterpenoid Conjugates Linked via Heterocyclic Linkers Enhance the Cytotoxic Effect of Topotecan.
Topics: Adamantane; Antineoplastic Agents; Camphor; Monoterpenes; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Topotecan | 2022 |